Logo

GILD

Gilead Sciences, Inc.

GILD

Gilead Sciences, Inc. • NASDAQ
$125.84 ▼ -1.31% (-1.67)
Market Cap $156.13 B
52w High $128.70
52w Low $88.57
Dividend Yield 3.14%
P/E 15.37
Volume 2.61M
Outstanding Shares 1.24B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $7.769B ▲ $2.873B ▼ $3.052B ▲ 39.284% ▲ $2.46 ▲ $4.583B ▲
Q2-2025 $7.081B ▲ $3.106B ▲ $1.96B ▲ 27.68% ▲ $1.57 ▲ $3.374B ▲
Q1-2025 $6.667B ▼ $2.89B ▼ $1.315B ▼ 19.724% ▼ $1.06 ▼ $2.605B ▼
Q4-2024 $7.569B ▲ $3.536B ▼ $1.783B ▲ 23.557% ▲ $1.43 ▲ $3.109B ▲
Q3-2024 $7.545B $5.083B $1.253B 16.607% $1 $1.884B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.349B ▲ $58.533B ▲ $37.077B ▲ $21.54B ▲
Q2-2025 $5.213B ▼ $55.721B ▼ $36.13B ▼ $19.675B ▲
Q1-2025 $7.926B ▼ $56.434B ▼ $37.356B ▼ $19.162B ▼
Q4-2024 $11.568B ▲ $58.995B ▲ $39.749B ▲ $19.33B ▲
Q3-2024 $6.697B $54.525B $36.135B $18.474B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $3.052B ▲ $4.108B ▲ $-427M ▲ $-1.489B ▲ $2.186B ▲ $3.961B ▲
Q2-2025 $1.96B ▲ $827M ▼ $-2.116B ▼ $-1.567B ▲ $-2.782B ▼ $720M ▼
Q1-2025 $1.315B ▼ $1.757B ▼ $-415M ▼ $-3.426B ▼ $-2.065B ▼ $1.653B ▼
Q4-2024 $1.783B ▲ $2.975B ▼ $-225M ▲ $2.26B ▲ $4.954B ▲ $2.828B ▼
Q3-2024 $1.253B $4.309B $-710M $-1.379B $2.265B $4.168B

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Cell Therapy Products Total Cell Therapy Product Sales
Cell Therapy Products Total Cell Therapy Product Sales
 $450.00M ▲$460.00M ▲$580.00M ▲$520.00M ▼
Other Products Total Other product sales
Other Products Total Other product sales
 $460.00M ▲$210.00M ▼$200.00M ▼$180.00M ▼
Products Other HIV
Products Other HIV
 $10.20Bn ▲$4.59Bn ▼$5.09Bn ▲$5.28Bn ▲
Trodelvy
Trodelvy
 $670.00M ▲$290.00M ▼$360.00M ▲$360.00M ▲
Veklury
Veklury
 $550.00M ▲$300.00M ▼$120.00M ▼$280.00M ▲
Liver Disease
Liver Disease
 $0 ▲$760.00M ▲$800.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Gilead’s sales over the last several years have been fairly steady, edging up rather than showing big growth spurts. The business still throws off strong gross profit, but profitability further down the income statement has been choppy. Operating income and net income were healthy for several years, then dropped sharply most recently, suggesting a mix of higher costs, heavy investment, and likely one‑off charges pulling down reported earnings. In plain terms: the company is selling a lot at good margins, but accounting profits have become more volatile as Gilead spends to reshape its portfolio and manages the maturing of older franchises.

Balance Sheet

Balance Sheet The balance sheet shows a large, established pharma company with meaningful debt but also solid resources. Total assets have drifted slightly lower, which is not alarming by itself, but does signal that Gilead is not in a rapid expansion phase. Debt remains sizable, although it has been edging down from earlier peak levels, while shareholder equity has gradually built up. Cash on hand has improved in the most recent year, giving the company more flexibility. Overall, the picture is of a leveraged but reasonably well‑supported balance sheet, backed by strong cash generation rather than a fortress‑like, net‑cash position.

Cash Flow

Cash Flow Cash generation is one of Gilead’s key strengths. Operating cash flow has been consistently strong and comfortably above its spending on equipment and facilities, leaving robust free cash flow year after year. Capital spending needs are relatively modest compared with cash coming in, which supports ongoing R&D, acquisitions, debt service, and shareholder returns. Even in years when reported earnings look weak, the underlying cash flow has remained solid, which helps cushion the impact of income statement volatility.

Competitive Edge

Competitive Edge Gilead remains a powerhouse in antiviral medicines, especially in HIV, where it holds a leading and sticky position thanks to effective, convenient therapies and strong relationships with prescribers. Its earlier breakthrough in Hepatitis C and its COVID treatment underscored its scientific depth in virology, even though revenue from those areas has matured or normalized. The company benefits from a broad patent estate, brand trust, and large‑scale manufacturing and distribution, all of which form a real competitive moat. The main competitive pressures are patent expirations over time, intensifying rivalry in HIV and oncology, pricing and reimbursement scrutiny, and the need to replace revenue from aging products with newer therapies.

Innovation and R&D

Innovation and R&D Innovation is still at the core of Gilead’s story. The company is pushing beyond daily HIV pills into long‑acting injectables, such as its twice‑yearly HIV treatment and prevention therapy, which could reshape how patients manage the disease. In oncology, Gilead has moved aggressively via acquisitions into cell therapies and antibody‑drug conjugates, aiming to build a second major growth pillar beyond virology. It is also developing drugs in inflammation and liver disease to diversify further. This strategy brings opportunity but also risk: high R&D costs, clinical trial uncertainty, integration challenges for acquired assets, and the constant pressure to deliver successful late‑stage data to offset expiring patents.

Summary

Overall, Gilead looks like a mature biopharma leader in transition. Revenues are stable with modest growth, and the company continues to generate strong cash flow, even as reported earnings have become more uneven. The balance sheet carries meaningful debt but is supported by reliable cash generation. Competitively, Gilead still enjoys a powerful position in HIV and virology, with patents, expertise, and scale forming a durable moat. The key question for the next phase is execution: can Gilead’s investments in long‑acting HIV therapies, oncology, and inflammatory and liver diseases successfully replace and expand on its older franchises, while managing costs and competition? The data suggest a business with solid foundations, using its cash and scientific base to reposition for its next wave of growth, but with the usual biopharma uncertainties around pipeline success and pricing pressure.

NEWS

November 24, 2025 · 8:30 AM UTC

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Read more

November 20, 2025 · 7:02 AM UTC

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Read more

November 18, 2025 · 5:00 AM UTC

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Read more

November 13, 2025 · 8:30 AM UTC

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Read more

November 10, 2025 · 4:00 AM UTC

AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit

Read more